1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Ambu A/S

Ambu A/S

AMBBY
Ambu A/SUS flagOther OTC
10.17
USD
- -
- -
2.69BMarket Cap
Ambu A/S
AMBBY
(Other OTC)

Recent

price

10.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4
4.21
4.48
5.91
6.68
7.86
8.79
9.94
10.72
11.54
14.47
15.94
17.5
18.33
20.24
- -
22.36
Revenue per Share
0.36
0.3
0.47
0.2
0.64
0.63
1.05
1.27
1.39
1.3
0.98
0.98
0.37
0.64
0.88
- -
1.35
Basic EPS, GAAP
0.13
0.25
0.55
0.52
0.73
0.87
1.31
1.95
1.31
1.11
-0.55
-1.02
-1.8
0.74
1.97
- -
1.41
Free Cash Flow per Basic Share
0.08
0.12
0.1
0.15
0.06
0.19
0.19
0.32
0.38
0.41
0.39
0.29
0.3
- -
- -
- -
0.38
Dividend per Share
2.33
2.35
2.62
2.73
3.2
3.47
3.17
4.5
6.96
7.9
9.03
14.98
15.28
19.89
20.46
- -
22.02
Book Value per Share
1.46
1.53
1.87
-1.16
-0.62
-0.21
-1.05
0.27
-3.12
-2.48
-2.28
2.81
2.53
6.84
8.88
- -
10.02
Tangible Book Value per Share
235
234
233
234
237
240
237
237
243
244
247
252
254
260
266
267
267
Basic Weighted Avg Shares
940
983
1,045
1,383
1,584
1,889
2,084
2,355
2,606
2,820
3,567
4,013
4,444
4,775
5,391
- -
5,958
Sales/Revenue/Turnover
12.59
14.68
14.45
11.42
12.5
12.76
17.08
19.53
21.6
17.02
12
8.47
2.75
6.32
11.96
- -
13.16
Operating Margin (%)
61
56
53
74
88
96
102
105
115
109
181
216
351
348
696
- -
704
Depreciation Expense
84
69
110
48
151
152
250
301
337
317
241
247
93
168
235
- -
359
Net Income, GAAP
27.58
29.42
23.61
31.43
27.4
29.3
23.31
23.41
27.53
23.24
25.16
19.81
14.68
20
21.67
- -
15.33
Effective Tax Rate (%)
8.94
7.04
10.53
3.47
9.53
8.05
12
12.78
12.93
11.24
6.76
6.15
2.09
3.52
4.36
- -
6.03
Profit Margin (%)
206
231
297
298
351
400
381
-284
511
154
197
628
1,143
1,066
1,578
- -
1,929
Working Capital
44
30
18
753
702
700
925
83
1,304
1,151
1,401
760
1,766
512
483
- -
459
LT Debt
562
580
665
651
854
1,036
990
1,279
1,882
2,182
2,372
3,952
4,261
5,393
5,594
- -
5,905
Total Equity
13.17
14.39
15.39
9.73
9.07
9.46
13.94
17.13
15.29
11.06
8.91
6.37
1.91
4.01
8.32
- -
10.32
Return on Invested Capital (%)
14.1
11.72
16.47
5.83
11.92
10.8
16.28
18.15
14.81
10.92
7.75
6.48
2.33
3.77
4.35
- -
6.28
Return on Capital (%)
16.49
12.62
18.97
7.69
21.62
19.11
31.55
33.1
24.43
17.49
11.59
8.24
2.43
3.71
4.42
- -
6.28
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
ST Debt
75
76
75
LT Borrowings
- -
- -
- -
LT Finance Leases
489
478
459
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
266
266
266
Market Capitalization
25,130
31,413
26,493

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'25
Total Current Assets
2,808
2,891
2,943
Cash, Cash Equivalents & STI
588
640
751
Accounts Receivable, Net
826
877
852
Inventories
1,228
1,214
1,193
Total Current Liabilities
1,078
1,003
1,014
Payables & Accruals
- -
- -
- -
ST Debt
75
76
75
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,254
1,367
1,383
1,387
5,391
2025
1,510
1,554
1,507
- -
- -
2026
1,558
1,573
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.54
0.5
-0.51
0.88
2025
0.68
0.71
0.46
- -
- -
2026
0.44
0.46
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.3
0.08
- -
- -
- -
2026
0.34
0.08
- -
- -
- -
Similar Companies
MediPress Health-Limited Partnership (MPRS.TA)
Luxbright AB (publ) (LXB.ST)
Titan Medical Inc. (TMD.TO)
Cerus Corporation (CERS)
InspireMD, Inc. (NSPR)
Coala-Life Group AB (publ) (COALA.ST)
Business
Ambu A/S develops, manufactures and markets single-use medical devices for endoscopy solutions and anesthesia & patient monitoring to hospitals, clinics, private practices and emergency services worldwide. The company offers a comprehensive portfolio of single-use endoscopes across pulmonology (including aScope Broncho), urology (including aScope Cysto), ear-nose-throat (including RhinoLaryngo) and gastroenterology (including aScope Gastro); video laryngoscopes such as SureSight Connect; airway management products including the Ambu Bag self-inflating resuscitator, laryngeal masks and ventilation devices; and diagnostic electrodes such as BlueSensor and Neuroline for ECG and neurophysiological monitoring. Founded in 1937 and headquartered in Ballerup, Denmark, Ambu operates production facilities in the US, China, Malaysia and Mexico, with sales in more than 100 countries and North America accounting for over 50% of revenue. In September 2025, the company launches its ZOOM AHEAD strategy, building on the successful ZOOM IN plan from 2022 by raising its five-year organic revenue growth target to 11-13% CAGR through FY 2029/30, targeting 15-20% growth in Endoscopy Solutions, and aspiring to global leadership in single-use endoscopy while planning acquisitions in 2025/26; it also earns Frost & Sullivan's 2025 Technology Innovation Leadership Recognition for its advancements in the European single-use endoscopy market.

Company News

APIChat

  • defenseworld.net

    Ambu A/S (OTCMKTS:AMBBY) Sees Large Volume Increase – What’s Next?

  • defenseworld.net

    Ambu A/S (OTCMKTS:AMBBY) Trading 3.4% Higher – Still a Buy?